Clinical Trials

Vedanta begins phase 2 trial of LBP candidate VE303 for rCDI

Vedanta Biosciences, which was founded by PureTech Health, has commenced a phase 2 study of its rationally-defined bacterial consortium product candidate, VE303, for recurrent Clostridium difficile infection (rCDI).

Janssen’s Tremfya meets primary endpoint in phase 3 psoriasis trial

Janssen Pharmaceutical said that Tremfya (guselkumab) was found to be superior to Cosentyx (secukinumab) for the primary endpoint assessed at week 48 of a phase 3 trial in adults with moderate to severe plaque psoriasis.

Ra Pharma’s zilucoplan meets primary endpoints in phase 2 gMG trial

Ra Pharmaceuticals’ (Ra Pharma) zilucoplan has succeeded in a phase 2 trial in generalized myasthenia gravis (gMG) by meeting the primary and key secondary end points.

BMS, Vedanta Biosciences to evaluate Opdivo-VE800 combo in metastatic cancers

Bristol-Myers Squibb will evaluate Opdivo (nivolumab) in combination with Vedanta Biosciences’ VE800, a live biotherapeutic product (LBP), in patients with advanced or metastatic cancers.

Eisai, UCL to launch phase I trials of E2814 for Alzheimer’s disease

Eisai said that the first investigational drug candidate from its drug discovery collaboration with University College London (UCL) is set to enter Phase I clinical trials for Alzheimer's disease (AD) in early 2019.

AstraZeneca’s Imfinzi fails to improve OS in head and neck cancer trial

AstraZeneca said that the combination of its Imfinzi (durvalumab) monotherapy and tremelimumab has failed to improve overall survival (OS) rate compared to standard-of-care (SoC) chemotherapy in a head and neck cancer trial.

Novartis initiates phase III trials of ligelizumab in urticaria

Novartis has initiated phase III trials for its monoclonal anti-IgE antibody ligelizumab (QGE031) in chronic spontaneous urticaria (CSU) patients whose symptoms are inadequately controlled by H1-antihistamines.

Ixico secures expanded contract from major biopharmaceutical firm

Data analytics company Ixico has signed an expanded scope to an existing contract with a top 10 biopharmaceutical company.

J&J’s Darzalex reduces disease progression in multiple myeloma study

Johnson & Johnson’s (J&J) Darzalex (daratumumab), in combination with lenalidomide and dexamethasone (Rd), has significantly reduced the risk of disease progression in multiple myeloma study.